XASX
WNX
Market cap3mUSD
Oct 09, Last price
0.08AUD
1D
0.00%
1Q
36.36%
IPO
-99.27%
Name
Wellnex Life Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Wellnex Life Limited, together with its subsidiaries, develops, markets, and sells health and wellness products in Australia, New Zealand, and the United Kingdom. The company offers topical anti-inflammatory creams, sprays, and roll-ons under the Pain Away brand; caffeine energy liquid capsules and multivitamins under the Wakey Wakey brand; sleep aid products under the Nighty Night brand; teeth whitening solutions under the Mr. Bright brand; pain relief capsules under the Wagner Liquigesics brand; medicinal cannabis under the Wellness Life brand; and over-the-counter medicines under the Pharmacy Own brand. It is also involved in the holding of intellectual properties and trademarks of its products; brand and pharma solution businesses; and investment activities. The company was formerly known as Wattle Health Australia Limited and changed its name to Wellnex Life Limited in June 2021. Wellnex Life Limited was incorporated in 2011 and is headquartered in Port Melbourne, Australia.
Key people
Peter Biantes
Interim Independent Non-Executive Chairman of the Board · since 2020
Tony McKenna
Group Chief Executive Officer, Managing Director · since 2020
Martin Glenister
Co-Founder, Director of Sales
George Karafotias
Chief Financial Officer · since 2019
Mark McCammon
Vice President Global Sales
Angela Coppola
Finance and Administration Executive
Yifang Wang Yvette
Client Engagement Specialist
Li Zheng
Company Secretary, Non-Executive Independent Director · since 2019
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑10 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||